Home » Stocks » Rubius Therapeutics

Rubius Therapeutics, Inc. (RUBY)

Stock Price: $6.25 USD 0.10 (1.63%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 502.98M
Revenue (ttm) n/a
Net Income (ttm) -179.36M
Shares Out 80.48M
EPS (ttm) -2.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $6.25
Previous Close $6.15
Change ($) 0.10
Change (%) 1.63%
Day's Open 6.27
Day's Range 6.05 - 6.30
Day's Volume 200,890
52-Week Range 3.35 - 16.16

More Stats

Market Cap 502.98M
Enterprise Value 354.73M
Earnings Date (est) Aug 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 80.48M
Float 35.71M
EPS (basic) -2.25
EPS (diluted) -2.26
FCF / Share -2.08
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.09M
Short Ratio 33.26
Short % of Float 26.88%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.27
Revenue n/a
Operating Income -184.05M
Net Income -179.36M
Free Cash Flow -166.93M
Net Cash 148.24M
Net Cash / Share 1.84
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -29.13%
ROE -59.12%
ROIC -51.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 3
Overweight 0
Hold 2
Underweight 1
Sell 0

Analyst Consensus: Overweight

Price Target

(60.00% upside)
Current: 6.25
Target: 10.00
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-170-91.66-43.26-10.85
Net Income-163-89.20-43.85-11.02
Shares Outstanding78.6939.298.027.20
Earnings Per Share-2.08-2.27-5.55-1.63
Operating Cash Flow-110-58.34-21.94-9.50
Capital Expenditures-40.66-14.95-2.25-0.44
Free Cash Flow-151-73.29-24.19-9.95
Cash & Equivalents2854061057.07
Total Debt97.0065.795.443.92
Net Cash / Debt18834199.133.14
Book Value274393-43.69-17.12
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Rubius Therapeutics, Inc.
Country United States
Employees 195
CEO Pablo J. Cagnoni

Stock Information

Ticker Symbol RUBY
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RUBY
IPO Date July 18, 2018


Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.